• 肿瘤基因检测
  • 药企合作
  • 燃石早检
  • 新闻动态

    新闻中心 学术成果

  • 患者专区
  • 关于燃石

    公司简介 合作伙伴 核心资质 管理团队 技术平台 加入我们 联系我们

  • Genomic Testing
  • Biopharma Partner Services
  • Early Detection
  • News & Activities

    News Publications

  • Patient Zone
  • About Us

    Overview Partners Qualifications Management Team Technologies Join Us Contact Us

  • INVESTORS

    • Yusheng Han CEO&Founder

    Founder of Burning Rock, established Burning Rock in 2014, engaged in investment of medical fields; with successful experience in establishing and operating a start-up team; with sixteen years of working experience in the field of life science.☆ Established Burning Rock☆ Investment manager of top-rank VC Northern Light Venture Capital☆ MBA from Columbia University☆ General manager of BioTek Instrument China Region☆ Cell biology master of Peking Union Medical College;

    Shannon ChuaiCSO

    Co-founder of Burning Rock. With nearly 20 years of experience in the field of bioinformatics and translational medicine, mastered internationally leading technologies, accumulated R& D experience in tumor individualistic diagnosis and treatment related areas such as NGS data analysis, molecular diagnosis,etc. ☆ Novartis (China) R& D Center: Supervisor of the bioinformatics platform☆ Chief Statistical Analyst of Novartis (America), University of Pennsylvania☆ Experiment designer and data analyst of Sloan-Katherine Cancer Center of New York☆ University of Pennsylvania: Biostatistics Ph.D.☆ University of Texas: Statistics and Applied Mathematics Master;

    Leo LiCFO

    Mr. Leo Li has served as our chief financial officer since the third quarter of 2019 and our director since the first quarter of 2020. ☆Mr. Li served as an investment director and later an executive director of Vision Knight Capital, or VKC, a private equity fund focusing on China's internet-driven sectors. ☆ Prior to VKC, Mr. Li worked at Morgan Stanley Asia Ltd.☆ Mr. Li attended University of Oxford from 2004 to 2008 and received a four-year Master of Physics degree. ☆ Mr. Li is a Chartered Financial Analyst. ;

    Joe ZhangCTO

    With working experience in the field of NGS for over 10 years. Ever participated in research and development of several products, successfully released kits such as Infinium Omni 2.5M-8, 5M-4 gene sub-typing chip, TruSeq Dual Index Sequencing, TruSeq DNA Ht, TruSeq Stranded RNA HT, TruSeq Exome, TruSeq Synthetic Long-Read DNA as a leader of the core team, and made outstanding contribution to the fast development of NGS☆ A senior scientist of Illumina. ☆ A senior researcher of genome science department of Howard Hughes Institute of Medicine of University of Washington☆ Duke University: Ph.D. of molecular genetics and microbiology;

    Simon WuVice President for Business Development

    With above ten years of experience in life science and medicine and with rich experience in marketing and project management☆ Co-founder of Burning Rock☆ Gene Co., Ltd. General manager for China Region with the department of large applied instrument☆ Gene Co., Ltd. Project manager for China Region (applied industry)☆ Nanjing Normal University Biotech;

    Dan Zhou Vice President of Strategic partnerships

    Focused on sales of in vitro diagnostic agent for above 16 years, with rich marketing management and business expansion capabilities.☆ Worked as a sales supervisor for South China region in QIAGEN Business Management (Shanghai) Co., Ltd.☆ Worked as a market explorer in South China regionBeijing Jinpujia Medical Technology Co., Ltd.☆ Gene (Hong Kong) Co., Ltd.: Sales of Denmark DAKO, America BD, Abbott VYSIS diagnosis reagent, pathology, streaming and blood departments of Guangdong and Fujian☆ Shandong Liming Polytechnic Vocational College;